Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingqiao Kangbindu Granules is a Traditional Chinese Medicine (TCM) formulation primarily developed and manufactured by Shandong Buchang Pharmaceuticals. It is indicated for the treatment of viral influenza, upper respiratory tract infections, and associated symptoms such as fever, sore throat, and cough. The formulation typically includes botanical extracts such as *Forsythia suspensa* (Qingqiao), *Lonicera japonica* (Honeysuckle), and *Isatis indigotica* (Radix Isatidis), which are traditionally used for their heat-clearing and detoxifying properties. In modern pharmacological terms, these components are studied for their broad-spectrum antiviral and anti-inflammatory activities. The drug is approved by the National Medical Products Administration (NMPA) in China and is widely used as a proprietary Chinese medicine for seasonal respiratory viral infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qingqiao kangbindu keli.